| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.48 | 2e-40 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.41 | 1e-31 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.39 | 3e-31 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.4 | 4e-29 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.39 | 7e-29 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.37 | 2e-28 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.37 | 6e-25 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.37 | 6e-24 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.32 | 3e-20 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.32 | 3e-19 |